ParkinsonCanadaV1, Main, Exploration, bibRecord, 002371

Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease

Identifieur interne : 002371 ( Main/Exploration ); précédent : 002370; suivant : 002372

Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease

Auteurs : Patrick Fitzgerald [Irlande (pays)] ; Arkady Mandel [Canada] ; Anthony E. Bolton [Irlande (pays)] ; Aideen M. Sullivan [Irlande (pays)] ; Yvonne Nolan [Irlande (pays)]

Source :

Behavioural brain research [ 0166-4328 ] ; 2008.

RBID : Pascal:09-0008021

Descripteurs français

Pascal (Inist)
- Traitement, Multicatalytic endopeptidase complex, Inhibition, Maladie de Parkinson, Ubiquitine, Comportement en champ libre, Dopamine.

English descriptors

KwdEn :
- Dopamine, Inhibition, Multicatalytic endopeptidase complex, Open field behavior, Parkinson disease, Treatment, Ubiquitin.

Abstract

Failure of the ubiquitin-proteasome system to degrade abnormal proteins may underlie the accumulation ofa-synuclein and dopaminergic neuronal degeneration that occurs in Parkinson's disease. Consequently, a reduction of functional proteasome activity has been implicated in Parkinson's disease. VP025 (Vasogen Inc.) is a preparation of phospholipid nanoparticles incorporating phosphatidylglycerol that has been shown to have neuroprotective effects. We show that VP025 prevents the deficits in motor coordination and dopamine observed in a proteasome inhibitor rat model of PD. Thus, VP025 may have a therapeutic effect on the impairment ofdopaminergic-mediated motor activity induced by proteasome inhibition.

Affiliations:

Canada, Irlande (pays)

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000586
to stream PascalFrancis, to step Corpus: 000605
to stream PascalFrancis, to step Curation: 000706
to stream PascalFrancis, to step Checkpoint: 000505
to stream Main, to step Merge: 002566
to stream Main, to step Curation: 002371

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease</title>
<author><name sortKey="Fitzgerald, Patrick" sort="Fitzgerald, Patrick" uniqKey="Fitzgerald P" first="Patrick" last="Fitzgerald">Patrick Fitzgerald</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Vasogen Ireland Ltd</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Vasogen Ireland Ltd</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Anatomy and Neuroscience, University College Cork</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Cork</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mandel, Arkady" sort="Mandel, Arkady" uniqKey="Mandel A" first="Arkady" last="Mandel">Arkady Mandel</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Vasogen Inc</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vasogen Inc</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bolton, Anthony E" sort="Bolton, Anthony E" uniqKey="Bolton A" first="Anthony E." last="Bolton">Anthony E. Bolton</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Vasogen Ireland Ltd</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Vasogen Ireland Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sullivan, Aideen M" sort="Sullivan, Aideen M" uniqKey="Sullivan A" first="Aideen M." last="Sullivan">Aideen M. Sullivan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Anatomy and Neuroscience, University College Cork</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Cork</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nolan, Yvonne" sort="Nolan, Yvonne" uniqKey="Nolan Y" first="Yvonne" last="Nolan">Yvonne Nolan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Anatomy and Neuroscience, University College Cork</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Cork</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0008021</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 09-0008021 INIST</idno>
<idno type="RBID">Pascal:09-0008021</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000586</idno>
<idno type="stanalyst">FRANCIS 09-0008021 INIST</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000605</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000706</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000505</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000505</idno>
<idno type="wicri:doubleKey">0166-4328:2008:Fitzgerald P:treatment:with:phosphotidylglycerol</idno>
<idno type="wicri:Area/Main/Merge">002566</idno>
<idno type="wicri:Area/Main/Curation">002371</idno>
<idno type="wicri:Area/Main/Exploration">002371</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease</title>
<author><name sortKey="Fitzgerald, Patrick" sort="Fitzgerald, Patrick" uniqKey="Fitzgerald P" first="Patrick" last="Fitzgerald">Patrick Fitzgerald</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Vasogen Ireland Ltd</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Vasogen Ireland Ltd</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Anatomy and Neuroscience, University College Cork</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Cork</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mandel, Arkady" sort="Mandel, Arkady" uniqKey="Mandel A" first="Arkady" last="Mandel">Arkady Mandel</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Vasogen Inc</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vasogen Inc</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bolton, Anthony E" sort="Bolton, Anthony E" uniqKey="Bolton A" first="Anthony E." last="Bolton">Anthony E. Bolton</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Vasogen Ireland Ltd</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Vasogen Ireland Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sullivan, Aideen M" sort="Sullivan, Aideen M" uniqKey="Sullivan A" first="Aideen M." last="Sullivan">Aideen M. Sullivan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Anatomy and Neuroscience, University College Cork</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Cork</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nolan, Yvonne" sort="Nolan, Yvonne" uniqKey="Nolan Y" first="Yvonne" last="Nolan">Yvonne Nolan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Anatomy and Neuroscience, University College Cork</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Cork</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Behavioural brain research</title>
<title level="j" type="abbreviated">Behav. brain res.</title>
<idno type="ISSN">0166-4328</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Behavioural brain research</title>
<title level="j" type="abbreviated">Behav. brain res.</title>
<idno type="ISSN">0166-4328</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term>
<term>Inhibition</term>
<term>Multicatalytic endopeptidase complex</term>
<term>Open field behavior</term>
<term>Parkinson disease</term>
<term>Treatment</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term>
<term>Multicatalytic endopeptidase complex</term>
<term>Inhibition</term>
<term>Maladie de Parkinson</term>
<term>Ubiquitine</term>
<term>Comportement en champ libre</term>
<term>Dopamine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Failure of the ubiquitin-proteasome system to degrade abnormal proteins may underlie the accumulation ofa-synuclein and dopaminergic neuronal degeneration that occurs in Parkinson's disease. Consequently, a reduction of functional proteasome activity has been implicated in Parkinson's disease. VP025 (Vasogen Inc.) is a preparation of phospholipid nanoparticles incorporating phosphatidylglycerol that has been shown to have neuroprotective effects. We show that VP025 prevents the deficits in motor coordination and dopamine observed in a proteasome inhibitor rat model of PD. Thus, VP025 may have a therapeutic effect on the impairment ofdopaminergic-mediated motor activity induced by proteasome inhibition.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Irlande (pays)</li>
</country>
</list>
<tree><country name="Irlande (pays)"><noRegion><name sortKey="Fitzgerald, Patrick" sort="Fitzgerald, Patrick" uniqKey="Fitzgerald P" first="Patrick" last="Fitzgerald">Patrick Fitzgerald</name>
</noRegion>
<name sortKey="Bolton, Anthony E" sort="Bolton, Anthony E" uniqKey="Bolton A" first="Anthony E." last="Bolton">Anthony E. Bolton</name>
<name sortKey="Fitzgerald, Patrick" sort="Fitzgerald, Patrick" uniqKey="Fitzgerald P" first="Patrick" last="Fitzgerald">Patrick Fitzgerald</name>
<name sortKey="Nolan, Yvonne" sort="Nolan, Yvonne" uniqKey="Nolan Y" first="Yvonne" last="Nolan">Yvonne Nolan</name>
<name sortKey="Sullivan, Aideen M" sort="Sullivan, Aideen M" uniqKey="Sullivan A" first="Aideen M." last="Sullivan">Aideen M. Sullivan</name>
</country>
<country name="Canada"><noRegion><name sortKey="Mandel, Arkady" sort="Mandel, Arkady" uniqKey="Mandel A" first="Arkady" last="Mandel">Arkady Mandel</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002371 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002371 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:09-0008021
   |texte=   Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease

Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri